1. Cher, ML, Bova, GS, Moore, DH, Small, EJ, Carroll, PR, Pin, SS, Epstein, JI, Isaacs, WB & Jensen, RH (1996). Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56: 3091–3102.
2. Culig, Z, Hobisch, A, Cronauer, MV, Cato, ACB, Hittmair, A, Radmayr, C, Eberle, J, Bartsch, G & Klocker, H (1993a). Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7: 1541–1550.
3. Culig, Z, Klocker, H, Eberle, J, Kaspar, F, Hobisch, A, Cronauer, MV & Bartsch, G (1993b). DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 22: 11–22.
4. Culig, Z, Hobisch, A, Cronauer, MV, Radmayr, C, Trapman, J, Hittmair, A, Bartsch, G & Klocker, H (1994). Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474–5478.
5. Cronauer, MV, Klocker, H, Talasz, H, Geisen, FH, Hobisch, A, Radmayr, C, Böck, G, Culig, Z, Schirmer, M, Reissigl, A, Bartsch, G & Konwalinka, G (1996). Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate 28: 172–181.